Hyperexpression of PTAFR and PF4 as Possible Platelet Risk Biomarkers in Patients With COVID-19
In Vivo · 2024
DOI: 10.21873/invivo.13766 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Lívia DE Oliveira Sales und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil. Hauptthemen laut MEDLINE: COVID-19, Platelet Factor 4, Biomarkers, SARS-CoV-2. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: SARS-CoV-2 infection presents different severity levels that suggest the influence of genetic factors on the clinical outcome of the disease. In cases of severe COVID-19, the presence of elevated coagulation markers, increased platelet activation and aggregation and the risk of thrombotic complications are described. Given the participation of these cells in several serious viral infections and their negative role when associated with a prothrombotic response, it is important to understand the mechanistic role of SARS-CoV-2 in platelet physiology. This study evaluated the hyperexpression of platelet-activating factor receptor (PTAFR) and platelet factor 4 (PF4) in unvaccinated and hospitalized patients with COVID-19. PATIENTS AND METHODS: The study included 43 COVID-19 patients stratified according to WHO guidelines. Subsequently, the expression of the PTAFR and PF4 genes were evaluated using the real-time quantitative PCR and their possible correlation with the severity of the disease and clinical variables including hospitalization, outcome, sex, age and laboratory parameters (platelet count, INR and D-dimer). RESULTS: The analysis demonstrated a significant (p 0.05) different between patients stratified according to clinical variables. CONCLUSION: The expression of PTAFR and PF4 suggests an important molecular pathway in the pathophysiology of the disease and may be valuable platelet biomarkers to indicate increased risk in patients with COVID-19 who require hospital care, contributing to personalized intervention strategies and improving their clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil.
- Clementino Fraga Group, Central Unity, Molecular Biology Laboratory, Fortaleza, CE, Brazil.
- Department of Biological Sciences, Oncology Research Center, Federal University of Pará, Belém, PA, Brazil.
- Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil; carolfam@gmail.com.
Zitieren
APA
DE Oliveira Sales, L., DA Silva, J. B. S., DE Pinho Pessoa, F. M. C., Dias Nogueira, B. M., DE Oliveira, L. L. B., Khayat, A. S., DE Moraes Filho, M. O., DE Moraes, M. E. A., Montenegro, R. C., & Moreira-Nunes, C. A. (2024). Hyperexpression of PTAFR and PF4 as Possible Platelet Risk Biomarkers in Patients With COVID-19. In Vivo. https://doi.org/10.21873/invivo.13766
Vancouver
DE Oliveira Sales L, DA Silva JBS, DE Pinho Pessoa FMC, Dias Nogueira BM, DE Oliveira LLB, Khayat AS, et al. Hyperexpression of PTAFR and PF4 as Possible Platelet Risk Biomarkers in Patients With COVID-19. In Vivo. 2024. doi:10.21873/invivo.13766
BibTeX
@article{DEOliveiraSales2024,
author = {DE Oliveira Sales, Lívia and DA Silva, Jean Breno Silveira and DE Pinho Pessoa, Flávia Melo Cunha and Dias Nogueira, Beatriz Maria and DE Oliveira, Lais Lacerda Brasil and Khayat, André Salim and DE Moraes Filho, Manoel Odorico and DE Moraes, Maria Elisabete Amaral and Montenegro, Raquel Carvalho and Moreira-Nunes, Caroline Aquino},
title = {Hyperexpression of PTAFR and PF4 as Possible Platelet Risk Biomarkers in Patients With COVID-19},
journal = {In Vivo},
year = {2024},
doi = {10.21873/invivo.13766}
}
EUVIMED